PARP inhibitor
Class of drugsWikipedia
71
MENTIONS
4
EPISODES
4
PODCASTS
Search complete. 71 mentions across 4 episodes found for "PARP inhibitor".
Oct 13, 2026
Jonathan LedermannSOUNDBITE_SPEAKER
She went ahead, had surgery, and then we gave her chemotherapy with carboplatin and liposomal doxorubicin.
Neil LoveHOST
If you could have accessed a PARP inhibitor in this patient with a recurrence three years after stopping olaparib/bev, would you have?
Jonathan LedermannSOUNDBITE_SPEAKER
Yes, I would, and I would have probably given her rucaparib, having had olaparib in the front line.
Jonathan LedermannSOUNDBITE_SPEAKER
But, you know, I could have equally given her [laughs] niraparib.
Jonathan LedermannSOUNDBITE_SPEAKER
I mean, the answer is, of course, we don't actually know to what extent patients will benefit from retreatment with a PARP inhibitor.
Jonathan LedermannSOUNDBITE_SPEAKER
And those studies need to be done, and some of them are being planned at the moment.
Shannon WestinMODERATOR
Great.
Shannon WestinMODERATOR
What do you...
Jonathan LedermannSOUNDBITE_SPEAKER
She went ahead, had surgery, and then we gave her chemotherapy with carboplatin and liposomal doxorubicin.
Neil LoveHOST
If you could have accessed a PARP inhibitor in this patient with a recurrence three years after stopping olaparib/bev, would you have?
Jonathan LedermannSOUNDBITE_SPEAKER
Yes, I would.
Jonathan LedermannSOUNDBITE_SPEAKER
And I would have probably given her rucaparib having had olaparib in the front line.
Jonathan LedermannSOUNDBITE_SPEAKER
But, you know, I could have equally given her [laughs] niraparib.
Jonathan LedermannSOUNDBITE_SPEAKER
I mean, the answer is, of course, we don't actually know to what extent patients will benefit from retreatment with a PARP inhibitor.
Jonathan LedermannSOUNDBITE_SPEAKER
And those studies need to be done, and some of them are being planned at the moment.
Shannon WestinMODERATOR
Great.
Jonathan LedermannSOUNDBITE_SPEAKER
She went ahead, had surgery, and then we gave her chemotherapy with carboplatin and liposomal doxorubicin.
Neil LoveHOST
If you could have accessed a PARP inhibitor in this patient with a recurrence three years after stopping olaparib/bev, would you have?
Jonathan LedermannSOUNDBITE_SPEAKER
Yes, I would, and I would have probably given her rucaparib, having had olaparib in the front line.
Jonathan LedermannSOUNDBITE_SPEAKER
But, you know, I could have equally given her [laughs] niraparib.
Jonathan LedermannSOUNDBITE_SPEAKER
I mean, the answer is, of course, we don't actually know to what extent patients will benefit from retreatment with a PARP inhibitor.
Jonathan LedermannSOUNDBITE_SPEAKER
And those studies need to be done, and some of them are being planned at the moment.
Shannon WestinMODERATOR
Great.
Shannon WestinMODERATOR
So I think we've got some very interesting things brought up w-with Dr. Ledermann's video, and I want to have our esteemed faculty answer some of these questions.
Amber WilliamsHOST
I'm your host, Amber Williams.
Amber WilliamsHOST
In today's episode, Dr. Neeraja Garwal and Dr. Emmanuel Antanarakis discuss the evolving role of PARP inhibitors in metastatic prostate cancer.
Amber WilliamsHOST
emphasizing early molecular testing to identify appropriate patients for PARP-directed therapy and proactive adverse event management to support treatment continuation.
Amber WilliamsHOST
This episode is part of a larger educational program titled Interactive Decision Support for Metastatic Prostate Cancer, biomarker testing, PARP inhibitor selection, sequencing, and toxicity management in metastatic castration-sensitive and castration-resistant prostate cancer.
Neeraj AgarwalGUEST
I'm a GU medical oncologist at the Dana-Farber Cancer Institute in Boston.
Neeraj AgarwalGUEST
And here I have my esteemed friend and colleague, Dr. Emmanuel Antonorakis.
Neeraj AgarwalGUEST
a very well-known authority in the field of prostate cancer, and we'll be talking about PARP inhibitors in prostate cancer today.
Neeraj AgarwalGUEST
Welcome, Emmanuel.